0000899243-20-032667.txt : 20201203
0000899243-20-032667.hdr.sgml : 20201203
20201203160508
ACCESSION NUMBER: 0000899243-20-032667
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201201
FILED AS OF DATE: 20201203
DATE AS OF CHANGE: 20201203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Henn Matthew R.
CENTRAL INDEX KEY: 0001767321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 201366943
MAIL ADDRESS:
STREET 1: C/O SERES THERAPEUTICS, INC.
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-01
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001767321
Henn Matthew R.
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Common Stock
2020-12-01
4
M
0
26000
0.71
A
38000
D
Common Stock
2020-12-01
4
M
0
26250
9.89
A
64250
D
Common Stock
2020-12-01
4
M
0
27562
6.01
A
91812
D
Common Stock
2020-12-01
4
S
0
55706
26.56
D
36106
D
Common Stock
2020-12-01
4
S
0
26265
27.56
D
9841
D
Common Stock
2020-12-01
4
S
0
9841
28.34
D
0
D
Stock Option (Right to Buy)
0.71
2020-12-01
4
M
0
26000
0.00
D
2016-09-19
2024-08-06
Common Stock
26000
0
D
Stock Option (Right to Buy)
9.89
2020-12-01
4
M
0
26250
0.00
D
2024-08-06
Common Stock
26250
3750
D
Stock Option (Right to Buy)
6.01
2020-12-01
4
M
0
27562
0.00
D
2029-01-24
Common Stock
27562
45938
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.07 to $27.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.10 to $28.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.145 to $28.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option has vested as to 25% of the shares on January 26, 2018. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.
The option has vested as to 25% of the shares on January 25, 2020. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.
Chief Scientific Officer and EVP
/s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn
2020-12-03